STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
Globe Newswire8-03-2023, 18:00
ResMed Adopts New Operating Model to Accelerate Long-term Growth 10-11-2023, 04:05